New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export RADX’s income statement to Excel — free account
Radiopharm Theranostics Limited - Sponsored ADR
RADXRadiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.
0.63
0.04
−5.97%
After hours trading: 0.60, down 4.76%, last trade Fri 4:27pm Eastern.
Follow RADX
Alert me
Where the cash went Fiscal 2026, year to Jun 30, 2026
Free cash flow was −$35.8M: capital expenditures were more than operating cash flow. Cash fell by $17.0M. What is a cash flow statement?
- Free cash flow
- −$35.8M
- Returned to shareholders
- $0.00
- Debt, net
- $0.00 borrowed
- Change in cash
- −$17.0M over the period
| Operating cash flow | −35.8 |
|---|---|
| Free cash flow | −35.8 |
| Shares issued, net | +24.0 |
| Other | −5.1 |
| Change in cash | −17.0 |
Figures in millions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Jun '26 | Jun '25 | Jun '24 | |
|---|---|---|---|
Net Income |
(38.65) | (24.83) | (31.44) |
Depreciation & Amortization |
1.84 | 1.68 | 2.05 |
Non Cash Items (Other) |
4.49 | 3.23 | 9.70 |
Accounts Receivable Change |
(4.78) | (6.10) | 2.28 |
Accounts Payable Change |
1.29 | 0.33 | 2.30 |
Change in other assets and liabilities |
0.00 | 1.91 | 0.05 |
Operating Cash Flow |
(35.82) | (23.73) | (15.07) |
Change in intangibles (net) |
— | 1.94 | — |
Other investing activities |
(3.68) | (0.79) | — |
Investing cash flow |
(3.68) | 1.15 | — |
Repayment/Issuance of Debt (Net) |
— | (1.23) | 1.44 |
Equity Repurchase (Common, Net) |
24.01 | 34.96 | 19.44 |
Other financial activities |
(1.36) | (4.30) | (1.29) |
Financing cash flow |
22.65 | 29.42 | 19.59 |
Exchange Rate Adjustment |
(0.10) | (0.01) | (0.02) |
Change in Cash |
(16.95) | 6.83 | 4.51 |
Beginning Cash |
19.76 | 12.03 | 7.67 |
Ending Cash |
2.81 | 18.86 | 12.18 |
Stock Based Compensation |
1.63 | 1.23 | 1.73 |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 |
Assets Liabilities Change (Total) |
(3.50) | (3.85) | 4.63 |
Issuance/Purchase of Shares |
24.01 | 34.96 | 19.44 |
| Other line items | |||
Revenue per Employee |
0.13 | 0.17 | 0.03 |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 2, 2026